Publications by authors named "Daniel Huang"
Incidence of hepatobiliary malignancies in primary sclerosing cholangitis: systematic review and meta-analysis.
Clin Gastroenterol Hepatol
December 2024
Background And Aims: Primary sclerosing cholangitis (PSC) is a known risk factor for hepatobiliary malignancies. We conducted a systematic review and meta-analysis of published studies to determine the incidence and risk factors for hepatobiliary malignancies in people with PSC.
Methods: Pubmed and Embase databases were searched from inception to April 10, 2024 for cohort studies reporting data on the incidence of cholangiocarcinoma (CCA), hepatocellular carcinoma (HCC), or gallbladder cancer (GBC) in PSC.
Background: Major society guidelines recommend transarterial chemoembolization (TACE) as the standard of care for intermediate-stage hepatocellular carcinoma (HCC) patients. However, predicting treatment response remains challenging.
Aims: As artificial intelligence (AI) may predict therapeutic responses, this systematic review aims to assess the performance and effectiveness of radiomics and AI-based models in predicting TACE outcomes in patients with HCC.
Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are the leading causes of liver disease and are emerging as the main risk factors for primary liver cancer (PLC). However, updated global data on MASH remain scarce.
Methods: This study analyzed data from the Global Burden of Disease (GBD) study between 2000 and 2021 to assess the age-standardized incidence, mortality, and disability-adjusted life years (DALYs) from MASH-associated PLC, stratified by geographical region, sociodemographic index, age, and sex.
Background: Significant health disparities exist in metabolic dysfunction-associated steatotic liver disease (MASLD), driven by social determinants of health (SDOH). Few studies have explored neighborhood-level SDOH in MASLD.
Methods: This is a retrospective cohort study of patients with MASLD at a multi-state healthcare institution.
Background And Purpose: Stereotactic ablative body radiotherapy (SABR) is an effective treatment for localized renal cell carcinoma (RCC). However, the role of primary site SABR for locally recurrent or metastatic RCC is unclear. Here, we report outcomes of primary SABR across a diverse cohort of localized, recurrent, and metastatic RCC patients treated at our institution.
View Article and Find Full Text PDFBackground: Elevated levels of serum ferritin, a marker of hepatic iron overload and inflammation, may be associated with metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatic fibrosis.
Aim: To determine the prevalence of MASLD and significant hepatic fibrosis among patients with type 2 diabetes mellitus (T2DM) and hyperferritinaemia.
Methods: This is a cross-sectional analysis of a prospective cohort of 523 adults (64% female) aged 50-80 with T2DM and without a diagnosis of haemochromatosis.
Background & Aims: The epidemiology of adult primary liver cancer continues to evolve, owing to the increasing prevalence of metabolic disease, rising alcohol consumption, advances in vaccination for HBV, and antiviral therapy for HCV. Disparities in care and the burden of liver cancer between populations persist. We assess trends in the burden of liver cancer and contributions by various etiologies across 204 countries and territories from 2010 to 2021.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates the risk of hepatocellular carcinoma (HCC) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) and a low fibrosis-4 index (FIB-4), which is used to assess liver health.
- - Out of 613 participants diagnosed with MASLD-related HCC, 13% had a low FIB-4, with 26% among those without cirrhosis, indicating potential missed cases for further evaluation.
- - The findings suggest that current guidelines may fail to identify over a quarter of MASLD-related HCC patients without cirrhosis who present a low FIB-4, highlighting a need for updated clinical pathways.
Prevalence of Chronic Liver Disease in Cholangiocarcinoma: A Meta-Analysis.
Clin Gastroenterol Hepatol
October 2024
Article Synopsis
- Chronic liver disease is a significant risk factor for cholangiocarcinoma (CCA), but its prevalence among CCA patients was previously unclear.
- A meta-analysis included data from 118,068 CCA patients, finding that about 25% had chronic liver disease and over 10% had cirrhosis.
- The study revealed a stronger association between chronic liver disease and intrahepatic CCA compared to extrahepatic CCA, except for primary sclerosing cholangitis, which was linked to extrahepatic forms.
Background Aims: Cut-points for non-invasive tests (NITs) for risk stratification in metabolic dysfunction-associated steatotic liver disease (MASLD) were derived from predominantly non-Hispanic populations. It is unknown if these cut-points perform adequately in Hispanic individuals. We assessed the performance characteristics of current NIT cut-points among Hispanic patients and determined whether they could be further optimized.
View Article and Find Full Text PDFBackground: The global impact of COVID-19 has prompted profound shifts in public health policies. The epidemiology of respiratory infectious disease may change in the post-covid era. This study investigates the repercussions of these policies on respiratory infectious diseases, specifically the resurgence of severe influenza and enterovirus infections in the post-COVID-19 era.
View Article and Find Full Text PDFGlobally, nearly half of deaths from cirrhosis and chronic liver diseases (CLD) and three-quarters of deaths from hepatocellular carcinoma (HCC) occur in the Asia-Pacific region. Chronic hepatitis B is responsible for the vast majority of liver-related deaths in the region. Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common form of CLD, affecting an estimated 30% of the adult population.
View Article and Find Full Text PDFArticle Synopsis
- Metabolic dysfunction-associated steatohepatitis (MASH) is a major cause of liver disease, and changes in liver fat can be monitored using MRI proton-density-fat fraction (PDFF).
- A systematic review identified 39 clinical trials evaluating various drug treatments for MASH, focusing on their effectiveness in reducing liver fat as measured by MRI-PDFF.
- The study found aldafermin and pegozafermin to be the most effective therapies for reducing liver fat at 24 weeks, while other options like efinopegdutide and semaglutide also showed promising results for significant fat reduction.
Background And Aims: There are limited data on the progression of liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) in people with type 2 diabetes mellitus (T2DM) versus those without T2DM in biopsy-proven metabolic dysfunction-associated steatotic liver disease. We examined LSM progression in participants with T2DM versus those without T2DM in a large, prospective, multicenter cohort study.
Approach And Results: This study included 1231 adult participants (62% female) with biopsy-proven metabolic dysfunction-associated steatotic liver disease who had VCTEs at least 1 year apart.
Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study.
J Clin Transl Hepatol
July 2024
Article Synopsis
- The study aimed to evaluate the effectiveness and tolerability of direct-acting antiviral (DAA) treatments for hepatitis C virus (HCV) across different genotypes (GTs) in a global, real-world context, focusing particularly on GT3 and GT6.
- Researchers analyzed data from 15,849 chronic hepatitis C patients across Asia, North America, and Europe over a seven-year period, noting demographic factors such as age, sex, and prior treatment history.
- Results showed a high sustained virological response (SVR12) rate of 96.9% overall, with variances by genotype, highlighting that independent factors like advanced age, cirrhosis, and previous treatment failures affected treatment outcomes, while being
Background: Although the burden of alcohol-associated hepatocellular carcinoma (HCC) is increasing with rising alcohol consumption, clinical presentation and outcomes of alcohol-associated HCC have not been systematically assessed. We aimed to determine the prevalence, clinical characteristics, surveillance rates, treatment allocation, and outcomes of alcohol-associated HCC.
Methods: Medline and Embase were searched from inception to January 2023.
Article Synopsis
- - The study analyzed data from the United Network for Organ Sharing between 2000 and 2022 to evaluate how the causes of liver disease impact liver transplantation outcomes for individuals with hepatocellular carcinoma (HCC), focusing on differences between men and women.
- - Findings revealed that nonalcoholic steatohepatitis (NASH) is the fastest-growing cause of liver disease in women and has surpassed chronic hepatitis C as the leading cause for both genders on transplant waitlists.
- - Women with HCC experience longer wait times for liver transplants and have lower rates of receiving transplants compared to men, though they tend to have better posttransplant survival rates when suffering from NASH-related HCC.
Article Synopsis
- Oral antiviral therapy for chronic hepatitis B (CHB) is effective and well-tolerated, but real-world data on how well patients are evaluated and treated is limited, prompting this study.
- In a cross-sectional analysis of 12,566 adult patients from 25 centers across 9 countries, it was found that 73.3% received adequate evaluation, with only 32.6% of those deemed treatment-eligible actually starting antiviral therapy.
- Factors influencing evaluation and treatment included gender, with females more likely to be evaluated but less likely to start treatment, and geographical differences, particularly among Asian patients from Western regions showing lower rates of evaluation and treatment.
The Burden of Overweight and Obesity-Associated Gastrointestinal Cancers in Low and Lower-Middle-Income Countries: A Global Burden of Disease 2019 Analysis.
Am J Gastroenterol
June 2024
Article Synopsis
- * Using data from the Global Burden of Disease Study 2019, the study found rising mortality rates from GI cancers related to high body mass index (BMI) in LICs and lower MICs, unlike in wealthier nations where rates have stabilized or decreased.
- * The findings highlight the growing public health concern of obesity-related GI cancer mortality in LICs and lower MICs, stressing the need for urgent measures to address the obesity epidemic in these regions.
Background And Aims: Magnetic resonance elastography (MRE) and vibration-controlled transient elastography (VCTE) have the potential to assess disease progression; however, repeatability data in people with cirrhosis are lacking. We aimed to assess the effect of disease severity on measurement variability and contribute to the evidentiary basis for the qualification of repeating liver stiffness measurements (LSM) in practice and research.
Methods: This prospective study included 49 adult participants (58.